Mymetics Corp
Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; and nationa… Read more
Mymetics Corp (MYMX) - Net Assets
Latest net assets as of September 2023: $-75.57 Million USD
Based on the latest financial reports, Mymetics Corp (MYMX) has net assets worth $-75.57 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($100.00K) and total liabilities ($75.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-75.57 Million |
| % of Total Assets | -75570.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 356.2 |
Mymetics Corp - Net Assets Trend (1998–2022)
This chart illustrates how Mymetics Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mymetics Corp (1998–2022)
The table below shows the annual net assets of Mymetics Corp from 1998 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-64.90 Million | -8.01% |
| 2021-12-31 | $-60.09 Million | -8.55% |
| 2020-12-31 | $-55.35 Million | -8.11% |
| 2019-12-31 | $-51.20 Million | -8.87% |
| 2018-12-31 | $-47.02 Million | -9.67% |
| 2017-12-31 | $-42.88 Million | -10.57% |
| 2016-12-31 | $-38.78 Million | -17.90% |
| 2015-12-31 | $-32.89 Million | -9.32% |
| 2014-12-31 | $-30.09 Million | -11.04% |
| 2013-12-31 | $-27.10 Million | +18.47% |
| 2012-12-31 | $-33.23 Million | -17.28% |
| 2011-12-31 | $-28.34 Million | -32.63% |
| 2010-12-31 | $-21.37 Million | -13.56% |
| 2009-12-31 | $-18.82 Million | -101.99% |
| 2008-12-31 | $-9.31 Million | -266.86% |
| 2007-12-31 | $-2.54 Million | +36.96% |
| 2006-12-31 | $-4.03 Million | +0.20% |
| 2005-12-31 | $-4.04 Million | -23.27% |
| 2004-12-31 | $-3.27 Million | +25.47% |
| 2003-12-31 | $-4.39 Million | -86.84% |
| 2002-12-31 | $-2.35 Million | -438.48% |
| 2001-12-31 | $694.58K | +552.34% |
| 2000-12-31 | $106.47K | -95.95% |
| 1999-12-31 | $2.63 Million | +43.72% |
| 1998-12-31 | $1.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mymetics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9574500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.53 Million | % |
| Other Comprehensive Income | $686.00K | % |
| Other Components | $34.44 Million | % |
| Total Equity | $-64.90 Million | 100.00% |
Mymetics Corp Competitors by Market Cap
The table below lists competitors of Mymetics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MIWA SUGAR LIMITED
SEM:MIWA
|
$22.08 |
|
CUTIX PLC
XNSA:CUTIX
|
$22.27 |
|
JAPAUL OIL & MARITIME SERVICES PLC
XNSA:JAPAULGOLD
|
$22.48 |
|
Acheter-Louer.Fr SA
F:2ZT1
|
$22.55 |
|
Tribe Technology PLC
LSE:TRYB
|
$22.04 |
|
BC Craft Supply Co. Ltd
PINK:CRFTF
|
$22.00 |
|
Guyana Gold Corp
PINK:GYGC
|
$21.85 |
|
HYBRIGENICS A-
BE:3HB
|
$21.76 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mymetics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -60,086,000 to -64,896,000, a change of -4,810,000.
- Net loss of 4,805,000 reduced equity.
- Other comprehensive income decreased equity by 5,000.
- Other factors decreased equity by 0.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.80 Million | -7.4% |
| Other Comprehensive Income | $-5.00K | -0.01% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Mymetics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $0.00 | $0.00 | x |
| 2001-12-31 | $0.02 | $0.00 | x |
| 2002-12-31 | $-0.05 | $0.00 | x |
| 2003-12-31 | $-0.09 | $0.00 | x |
| 2004-12-31 | $-0.05 | $0.00 | x |
| 2005-12-31 | $-0.06 | $0.00 | x |
| 2006-12-31 | $-0.04 | $0.00 | x |
| 2007-12-31 | $-0.02 | $0.00 | x |
| 2008-12-31 | $-0.05 | $0.00 | x |
| 2009-12-31 | $-0.10 | $0.00 | x |
| 2010-12-31 | $-0.11 | $0.00 | x |
| 2011-12-31 | $-0.12 | $0.00 | x |
| 2012-12-31 | $-0.11 | $0.00 | x |
| 2013-12-31 | $-0.09 | $0.00 | x |
| 2014-12-31 | $-0.10 | $0.00 | x |
| 2015-12-31 | $-0.11 | $0.00 | x |
| 2016-12-31 | $-0.13 | $0.00 | x |
| 2017-12-31 | $-0.14 | $0.00 | x |
| 2018-12-31 | $-0.15 | $0.00 | x |
| 2019-12-31 | $-0.17 | $0.00 | x |
| 2020-12-31 | $-0.18 | $0.00 | x |
| 2021-12-31 | $-0.20 | $0.00 | x |
| 2022-12-31 | $-0.21 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mymetics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -160166.67%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-152.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -1237.86% | -1040.22% | 0.57x | 2.07x | $-1.33 Million |
| 2001 | -2264.40% | 0.00% | 0.00x | 2.44x | $-15.80 Million |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.39 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.34 Million |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.10 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-842.42K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-582.21K |
| 2007 | 0.00% | -1200.56% | 2.44x | 0.00x | $-5.37 Million |
| 2008 | 0.00% | -10673.85% | 0.10x | 0.00x | $-6.01 Million |
| 2009 | 0.00% | -6790.67% | 0.01x | 0.00x | $-8.30 Million |
| 2010 | 0.00% | -5147.75% | 0.02x | 0.00x | $-9.29 Million |
| 2011 | 0.00% | -5988.07% | 0.02x | 0.00x | $-7.71 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.79 Million |
| 2013 | 0.00% | 137.02% | 0.33x | 0.00x | $8.71 Million |
| 2014 | 0.00% | -135.72% | 0.22x | 0.00x | $-247.10K |
| 2015 | 0.00% | -95.40% | 0.27x | 0.00x | $283.20K |
| 2016 | 0.00% | -475.98% | 0.15x | 0.00x | $-2.09 Million |
| 2017 | 0.00% | -2035.64% | 0.03x | 0.00x | $175.80K |
| 2018 | 0.00% | -5562.67% | 0.01x | 0.00x | $530.50K |
| 2019 | 0.00% | -3772.07% | 0.01x | 0.00x | $932.80K |
| 2020 | 0.00% | -11880.00% | 0.00x | 0.00x | $1.38 Million |
| 2021 | 0.00% | -157666.67% | 0.00x | 0.00x | $1.28 Million |
| 2022 | 0.00% | -160166.67% | 0.00x | 0.00x | $1.68 Million |
Industry Comparison
This section compares Mymetics Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mymetics Corp (MYMX) | $-75.57 Million | -1237.86% | N/A | $22.08 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |